Market Currents
Intuitive Surgical (ISRG +2.2%) should be bought , albeit selectively, says William Blair. The...
-
Wednesday, June 6, 2012, 3:00 PM ETIntuitive Surgical (ISRG +2.2%) should be bought , albeit selectively, says William Blair. The firm recommends using the recent weakness to pick it up. Its channel checks indicate the outlook for robotic surgery has never been stronger, however Zytiga drug approval is likely years away. The firm maintains an Outperform rating.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
